FluoGuide’s ownership to key patent registered

FluoGuide A/S ("FluoGuide", FLUO), today announces registration of ownership to the key patent family, which was acquired by FluoGuide prior to its IPO in April/May 2019. The patent family was issued nationally in the USA in 2018 and is valid until 2034. 

FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of their cure. It can also reduce costs for the health care system to the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in cancer patients by conducting a proof-of-concept clinical trial and announce the first result of this study during first half of 2020. 

The patent family (WO/2016/041558A1) including FG001 was issued nationally in the USA in 2018 and is valid until 2034. FluoGuide acquired this patent family prior to the IPO according to conditions previously communicated in the IPO prospectus. The registration of FluoGuide’s ownership (the assignment) of this issued US patent has now been officially confirmed by the United States Patent and Trademark Office.

Morten Albrechtsen, CEO of FluoGuide, comments: “We are happy to announce that FluoGuide’s ownership to the patent on FG001 is now registered. The patent is important for our operations and we are looking forward to report further progress on FG001 in the near future. During May and June 2019, we have been focusing on FG001 development to deliver on the targets that were communicated during our IPO.” 

Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

FluoGuide A/S
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark
www.fluoguide.com

Tags:

About Us

FluoGuide A/S develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Preclinical studies have demonstrated the potential of FG001 to vastly improve the likelihood of performing radical surgery (removal of all cancer) and thereby improving outcome and survival. FluoGuide is initially focused on glioblastoma (brain tumor) but the Company plan to expand its business to other solid tumors. Market launch of FG001 in a first country is expected in 2022/2023.

Subscribe

Documents & Links